Today’s, the parent company has the great role in managing and monitoring subsidiaries and companies and promoting their industrial activities. But, the main problem for pharmaceutical parent companies is the lack of clarity and confusion of   responsibilities between units .The successful parenting needs to create the element of 'fit' between the ways parent operates – parent characteristics – and   its business characteristics. However, the main parent characteristic is parent structure and restructuring is the main challenge in changing and unstable pharmaceutical market. In fact, the parent strategy should determine how value can be added to every organizational structure and parent structure should be proportionate to its dominant value creation strategy. The value drivers are very different in pharmaceutical industry regarding fast changing technology. The aim of this study is to explore an appropriate value-creating structure for the largest pharmaceutical parent company in Iran, TPICO. This study concentrates the sources of value in this special domain and restructuring the parent company by considering the dominant value-creating strategy and pharmaceutical value drivers.